Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms.

@article{Wiesner2010AlterationsOT,
  title={Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms.},
  author={T. Wiesner and A. C. Obenauf and C. Cota and I. Fried and M. Speicher and L. Cerroni},
  journal={The Journal of investigative dermatology},
  year={2010},
  volume={130 4},
  pages={
          1152-7
        }
}
  • T. Wiesner, A. C. Obenauf, +3 authors L. Cerroni
  • Published 2010
  • Biology, Medicine
  • The Journal of investigative dermatology
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive malignancy with a median survival of 12-14 months. To identify pathogenetic relevant genomic aberrations and molecular targets for therapy, we analyzed skin biopsy samples obtained from 14 patients using high-resolution array-based comparative genomic hybridization and immunostaining. Losses of chromosomes 9, 12, 13, and 15 were detected most frequently. Loss of the CDKN1B locus was the most common finding and… CONTINUE READING
    62 Citations
    Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm
    • 61
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 19 REFERENCES
    CD4(+) CD56(+) Lineage-Negative Malignancies Are Rare Tumors of Plasmacytoid Dendritic Cells
    • 69
    The murine gene p27Kip1 is haplo-insufficient for tumour suppression
    • 808
    CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC).
    • 169
    Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement.
    • 41
    • PDF
    The Regulation of INK4/ARF in Cancer and Aging
    • 851
    The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
    • 872
    • Highly Influential